drugset

drugset / Trial / NCT06400485

AMT-676 in Patients With Advanced Solid Tumors

NCT06400485 ↗

Phase 0 Recruiting 24 enrolled Multitude Therapeutics Inc.

NaSingle-groupOpen-labelTreatment

Summary

This is a first-in-human, open-label, multicenter Phase Ia/Ib study of AMT- 676, followed by an open-label, multicenter, dose-escalation.

Timeline

Start: 2024-06-18
Primary completion: 2027-05-15
Completion: 2027-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AMT-676	Other / unclassified	—	Intravenous

Indications